Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 501–600 of 1,001
Regnault, M. M., Castañeda-Sanabria, J., Tran, M. H. T. D., Beylot-Barry, M., Bachelez, H., Bénéton, N., Chosidow, O., Dupuy, A., Joly, P., Jullien, D., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15878 · Cited by 51
Galluzzo, M., D’Adamio, S., Silvaggio, D., Lombardo, P., Bianchi, L., & Talamonti, M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1708897 · Cited by 52
Role of Epigenetics in the Regulation of Immune Functions of the Skin
Sawada, Y., & Gallo, R. L. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.10.012 · Cited by 55
“Psoriasis is a representative Th17-mediated skin disease, and IL-17etargeted biologics are efficient therapies (Langley et al., 2014).”
BackgroundDragatin, C., Polus, F., Bodenlenz, M., Calonder, C., Aigner, B. A., Tiffner, K., Mader, J. K., Ratzer, M., Woessner, R., Pieber, T. R., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12863 · Cited by 50
Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
Garnock-Jones, K. P. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0143-7 · Cited by 50
“In the maintenance period of ERASURE and FIXTURE, response rates (PASI 75 and IGAmod2011) increased to week 16, then stabilized [19].”
BackgroundMethodInfluentialSegueni, N., Tritto, E., Bourigault, M.-L., Rose, S., Erard, F., Bert, M. L., Jacobs, M., Padova, F. D., Stiehl, D. P., Moulin, P., et al. (2016) · Scientific Reports · doi:10.1038/srep36923 · Cited by 61
Kurschus, F. C., & Moos, S. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.06.010 · Cited by 60
Psoriasis in Taiwan: From epidemiology to new treatments
Chiu, H., Wang, T., Chen, P.-H., Hsu, S.-H., Tsai, Y., & Tsai, T. (2018) · Dermatologica Sinica · doi:10.1016/j.dsi.2018.06.001 · Cited by 51
Psoriasis and hidradenitis suppurativa: A large-scale population-based study
Kridin, K., Shani, M., Schonmann, Y., Fisher, S., Shalom, G., Comaneshter, D. S., Batat, E., & Cohen, A. D. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.036 · Cited by 50
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study
Torres, T. R., Balato, A., Conrad, C., Conti, A., Dapavo, P., Ferreira, P., Gaiani, F. M., Leite, L., Malagoli, P., Mendes‐Bastos, P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.031 · Cited by 50
Valenzuela, L. M., Draibe, J. B., Fulladosa, X., Bestard, O., Cruzado, J. M., & Ambrós, J. T. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz029 · Cited by 53
“ustekinumab, respectively) are effectively used in other autoimmune conditions such as psoriasis [91], but no current studies are being conducted in vasculitis yet, despite the existence of a clear rationale, as described above.”
BackgroundRompoti, N., Katsimbri, P., Kokkalis, G., Boumpas, D., Ikonomidis, I., Theodoropoulos, K., Rigopoulos, D., & Papadavid, E. (2019) · Dermatologic Therapy · doi:10.1111/dth.13006 · Cited by 50
“The safety and efficacy profile of secukinumab was assessed in four randomized controlled trials (RCTs) (ERASURE, FEATURE, JUNCTURE, and FIXTURE) (Blauvelt et al., 2015; Langley et al., 2014; Paul et al., 2015).”
BackgroundResultInfluentialA New Generation of Treatments for Itch
Fowler, E., & Yosipovitch, G. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3347 · Cited by 54
“Keratinocytes are stimulated by IL-17A to secrete other pro-inflammatory mediators, which recruit neutrophils, Th17 cells, dendritic cells, and lymphoid cells (55).”
BackgroundInfluentialBagel, J., Blauvelt, A., Nia, J. K., Hashim, P. W., Patekar, M., de Vera, A., Ahmad, K. A., Paguet, B., Xia, S., Muscianisi, E., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16558 · Cited by 53
Alonso, S., Villa, I., Fernández, S., Martín-Varillas, J. L., Charca, L. C., Pino, M., Riancho, L., Morante, I., Santos, M., Brandy, A., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.679009 · Cited by 50
“Safety was analyzed by reviewing the clinical charts from the date of initiation of SEC, as well as the hospital admission records; the following were specifically checked: (1) Infections (type, microorganism, location and whether it was accompanied by bacteremia); (2) neoplasms (type, location, and stage); (3) Events…”
BackgroundMethodMagnolo, N., Kingo, K., Laquer, V. T., Browning, J., Reich, A., Szepietowski, J. C., Keefe, D. L., Mazur, R., Ghelani, P., Forrer, P., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.08.066 · Cited by 50
Augustin, M., Reich, K., Yamauchi, P., Pinter, A., Bagel, J., Dahale, S., You, R., Bruin, G. J. M., Djimopoulos, J., Paguet, B., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20971 · Cited by 50
Ricardo, J. W., & Lipner, S. R. (2020) · Dermatologic Therapy · doi:10.1111/dth.13687 · Cited by 55
Potential effects and mechanisms of Chinese herbal medicine in the treatment of psoriasis
Li, T., Gao, S., Han, W., Gao, Z., Wei, Y., Wu, G., Qiqiu, W., Chen, L., Feng, Y., Yue, S., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115275 · Cited by 56
Whibley, N., Jaycox, J. R., Reid, D. M., Garg, A. V., Taylor, J. A., Clancy, C. J., Nguyen, M. H., Biswas, P. S., McGeachy, M. J., Brown, G. D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500870 · Cited by 54
Galli‐Novak, E., Mook, S.-C., Büning, J., Schmidt, E., Zillikens, D., Thaçi, D., & Ludwig, R. J. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13499 · Cited by 49
Current challenges and emerging drug delivery strategies for the treatment of psoriasis
Hoffman, M. B., Hill, D., & Feldman, S. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1188801 · Cited by 52
“4% of patients treated with 300 mg of secukinumab achieved a PASI-90 response at week 16.[87] These success”
BackgroundT Helper 17 Cells in Primary Sjögren’s Syndrome
Matsui, K., & Sano, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6070065 · Cited by 51
Armstrong, A. W., Reich, K., Foley, P. A., Han, C., Song, M., Shen, Y., You, Y., & Papp, K. A. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0396-z · Cited by 56
Megna, M., Costanzo, L. D., Argenziano, G., Balato, A., Colasanti, P., Cusano, F., Galluccio, A. G., Gambardella, A., Lembo, S., Mozzillo, R., et al. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1622678 · Cited by 49
“For each patient the following data were collected through computer-based database or electronic registries: i) personal and demographic data; ii) duration of psoriasis and PsA (if available); iii) comorbidities; iv) previous psoriasis systemic treatments; v) duration of secukinumab therapy and eventual reason for its…”
BackgroundResultInfluentialWang, C. Y., Rademaker, M., Baker, C., & Foley, P. A. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13313 · Cited by 56
Bissonnette, R., Haydey, R. P., Rosoph, L. A., Lynde, C. W., Bukhalo, M., Fowler, J. F., Delorme, I., Gagné-Henley, A., Gooderham, M., Poulin, Y. P., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14647 · Cited by 54
New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice
Dubash, S., McGonagle, D., & Marzo‐Ortega, H. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317743486 · Cited by 48
Nash, P. T., McInnes, I. B., Mease, P. J., Thom, H. H. Z., Hünger, M., Karabis, A., Gandhi, K. K., Mpofu, S., & Jugl, S. M. (2018) · Rheumatology and Therapy · doi:10.1007/s40744-018-0106-6 · Cited by 50
Farhangian, M. E., & Feldman, S. R. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0131-y · Cited by 48
Psoriasis and Related Disorders
Burden, A. D., & Kirby, B. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0036 · Cited by 70
Chiricozzi, A., Romanelli, M., Saraceno, R., & Torres, T. R. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1228872 · Cited by 52
“Overall, secukinumab showed a positive impact on QoL, significantly improving Dermatology Life Quality Index (DLQI) score in treated patients participating to phase III trials [31,32].”
BackgroundDiagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology
Arnone, M., Takahashi, M. D. F., de Carvalho, A. V. E., Bernardo, W. M., Bressan, A. L., Ramos, A. M. C., Terena, A. C., Souza, C. D. S., Nunes, D. H., Bortoletto, M. C. D. C., et al. (2019) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.2019940211 · Cited by 65
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
Vidal, S., Puig, L., Carrascosa, J. M., González‐Cantero, Á., Ruiz‐Carrascosa, J., & Velasco-Pastor, A.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136740 · Cited by 48
“As observed with other IL-17A inhibitors, an adjusted higher rate of Candida infections, mostly mucosal or cutaneous candidiasis, have been reported, which is consistent with the important role of IL-17A against fungal infections [98].”
ResultOnset of vitiligo in a psoriasis patient on ixekizumab
Marasca, C., Fornaro, L., Martora, F., Picone, V., Fabbrocini, G., & Megna, M. (2021) · Dermatologic Therapy · doi:10.1111/dth.15102 · Cited by 47
Bimekizumab for the Treatment of Psoriasis
Freitas, E., Blauvelt, A., & Torres, T. R. (2021) · Drugs · doi:10.1007/s40265-021-01612-z · Cited by 58
A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response
Wu, D., Hailer, A., Wang, S., Yuan, M., Chan, J. S., Kurdi, A., Han, D., Ali, H., D’Angio, H. B., Mayer, A. T., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi2848 · Cited by 57
Defining Th‐cell subsets in a classical and tissue‐specific manner: Examples from the skin
Eyerich, S., & Zielinski, C. E. (2014) · European Journal of Immunology · doi:10.1002/eji.201444891 · Cited by 59
Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series
Weng, H.-J., Wang, T. ‐., & Tsai, T. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16252 · Cited by 47
Smith, M. K., Pai, J., Panaccione, R., Beck, P. L., Ferraz, J. G., & Jijon, H. B. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1067-0 · Cited by 50
Blauvelt, A., Shi, N., Burge, R. T., Malatestinic, W. N., Lin, C., Lew, C. R., Zimmerman, N. M., Goldblum, O. M., Zhu, B., & Murage, M. J. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.11.015 · Cited by 50
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist
Cherney, R. J., Cornelius, L. A. M., Srivastava, A., Weigelt, C. A., Marcoux, D., Duan, J. J. ‐., Shi, Q., Batt, D. G., Liu, Q., Yip, S. H., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00063 · Cited by 47
Armstrong, A. W., Soliman, A. M., Betts, K. A., Wang, Y., Gao, Y., Stakias, V., & Puig, L. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00647-0 · Cited by 47
“The included trials were: AMAGINE-2 [39], AMAGINE-3 [39], ECLIPSE [40], VOYAGE-1 [41], CLEAR [42], FIXTURE [43], CLARITY [44], IXORA-S [45], UltIMMa1 [46], UltIMMa2 [46], IMMerge [37], BE VIVID [7], BE RADIANT [10], and BE SURE [9].”
MethodEfficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
“IL-17A and IL-17F, have both demonstrated robust data for psoriasis [163,164].”
BackgroundVitamin B5 rewires Th17 cell metabolism via impeding PKM2 nuclear translocation
Chen, C., Zhang, W., Zhou, T., Liu, Q., Han, C., Huang, Z., Chen, S., Mei, Q., Zhang, C., Zhang, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111741 · Cited by 58
Wang, J., Wang, C., Liu, L., Hong, S., Ru, Y., Sun, X., Chen, J., Zhang, M., Lin, N., Li, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.993057 · Cited by 52
“Richard G 2014 (45) III PSO Secukinumab/ IL-17A 2044 (1438/606) 300; 150 i.”
Emerging drugs for the treatment of axial and peripheral spondyloarthritis
Braun, J., Kiltz, U., Heldmann, F., & Baraliakos, X. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.993378 · Cited by 47
Strober, B. E., Sigurgeirsson, B., Popp, G., Sinclair, R. D., Krell, J. M., Stonkus, S., Septe, M., Elewski, B. E., Gottlieb, A. B., Zhao, Y., et al. (2016) · International Journal of Dermatology · doi:10.1111/ijd.13236 · Cited by 46
MCPIP1 RNase Is Aberrantly Distributed in Psoriatic Epidermis and Rapidly Induced by IL-17A
Ruiz‐Romeu, E., Ferrán, M., Giménez‐Arnau, A. M., Bugara, B., Lipert, B. A., Jura, J., Florencia, E. F., Prens, E. P., Celada, A., Pujol, R. M., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.04.030 · Cited by 50
“INTRODUCTION The relevance of the T helper 17 (Th17) response in psoriasis is clinically evidenced by the therapeutic efficacy rates achieved by selective biologics targeting IL-17A and IL-17R in psoriatic patients (Langley et al., 2014; Leonardi et al., 2012; Papp, Leonardi, et al., 2012).”
BackgroundNoack, M., Ndongo-Thiam, N., & Miossec, P. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12830 · Cited by 47
Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies
Chyuan, I., & Chen, J.-Y. (2018) · Mediators of Inflammation · doi:10.1155/2018/2403935 · Cited by 54
“In psoriasis, phase III clinical trials for secukinumab have demonstrated that IL-17 inhibition therapy can achieve a 75% improvement of the Psoriasis Area and Severity Index (PASI75) in more than 75% of patients with plaque psoriasis response, and a significant portion of the patients also achieved PASI90 and PASI100…”
BackgroundAtopic-like dermatitis after secukinumab injection: A case report
Burlando, M., Cozzani, E., Russo, R. L., & Parodi, A. (2018) · Dermatologic Therapy · doi:10.1111/dth.12751 · Cited by 46
Chiu, H., Hui, R. C., Tsai, T., Chen, Y., Liao, N. C., Chen, P.-H., Lai, P.-J., Wang, T., & Huang, Y. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.035 · Cited by 46
Psoriasis: Past, Present, and Future
Billi, A. C., Gudjonsson, J. E., & Voorhees, J. J. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.08.437 · Cited by 55
“Loss of extracellular superoxide dismutase induces severe IL-23-mediated skin inflammation in mice.”
BackgroundInfluentialTomalin, L. E., Kim, J., Correa da Rosa, J., Lee, J., Fitz, L. J., Berstein, G., Valdez, H., Wolk, R., Krueger, J. G., & Suárez-Fariñas, M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.023 · Cited by 46
Benezeder, T., Painsi, C., Patra, V., Dey, S., Holcmann, M., Lange‐Asschenfeldt, B., Sibilia, M. C., & Wolf, P. (2020) · eLife · doi:10.7554/elife.56991 · Cited by 52
Secukinumab for rheumatology: development and its potential place in therapy
Koenders, M., & van den Berg, W. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s105263 · Cited by 53
Corbett, M. S., Chehadah, F., Biswas, M., Moe‐Byrne, T., Palmer, S., Soares, M. O., Walton, M., Harden, M., Ho, P., Woolacott, N. F., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21560 · Cited by 50
Wu, J. J., Feldman, S. R., Rastogi, S., Menges, B., Lingohr-Smith, M., & Lin, J. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1466022 · Cited by 49
IκBζ is a key player in the antipsoriatic effects of secukinumab
Bertelsen, T., Ljungberg, C., Litman, T., Huppertz, C., Hennze, R., Rønholt, K., Iversen, L., & Johansen, C. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.09.029 · Cited by 46
Kolbinger, F., Padova, F. D., Deodhar, A. A., Hawkes, J. E., Huppertz, C., Kuiper, T., McInnes, I. B., Ritchlin, C. T., Rosmarin, D. M., Schett, G. A., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107925 · Cited by 50
Penso, L., Bergqvist, C., Meyer, A., Herlemont, P., Weill, A., Zureik, M., Dray‐Spira, R., & Sbidian, É. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41923 · Cited by 49
“5) Cyclosporine 417 (2) 309 (2) 86 (1) MTX 5,844 (35) 5,305 (26) 2,741 (27) Infliximab 1,911 (11) 116 (1) 296 (3) ADA 5,551 (33) 437 (2) 1,900 (18) ETN 4,416 (26) 355 (2) – GOL 2,605 (16) 94 (1) 572 (6) Certolizumab 2,085 (12) 70 (1) 374 (4) UST 2,360 (14) 266 (1) 90 (1) Topical treatments 5,040 (30) 13,935 (68) 1,181…”
The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases
Oliva, M., Renert‐Yuval, Y., & Guttman‐Yassky, E. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000306 · Cited by 49
Secukinumab for ankylosing spondylitis and psoriatic arthritis
Lubrano, E., & Perrotta, F. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s100091 · Cited by 44
“For these reasons anti-IL-17A secukinumab was tested in psoriasis patients in two phase III, double-blind, randomized trials, ERASURE and FIXTURE, and showed a higher efficacy in Psoriasis Severity Index [PASI] 75 response compared to placebo and etanercept with a similar rate of infections compared to etanercept.(35)…”
Georgakopoulos, J. R., Ighani, A., Phung, M., & Yeung, J. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.11.036 · Cited by 44
“2%).(2,3) This may, in part, be due to patient dissatisfaction following minor disease relapse.”
BackgroundSawyer, L., Fotheringham, I., Wright, E., Yasmeen, N., Gibbons, C., & Moeller, A. H. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1427205 · Cited by 49
“6 FIXTURE (64,67) 12 10 12 Placebo 324 15.”
BackgroundGuselkumab for the treatment of psoriasis
Megna, M., Balato, A., Raimondo, A., & Balato, N. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1445223 · Cited by 43
The ties that bind: skin, gut and spondyloarthritis
Gracey, E., Dumas, E., Yerushalmi, M., Qaiyum, Z., Inman, R. D., & Elewaut, D. S. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000569 · Cited by 51
Ger, T.-Y., Huang, Y., Hui, R. C., Tsai, T., & Chiu, H. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319843756 · Cited by 44
State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis
Gisondi, P., Geat, D., Pizzolato, M., & Girolomoni, G. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.05.007 · Cited by 46
Reich, K., Warren, R. B., Coates, L. C., & Comite, G. D. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16124 · Cited by 45
Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis
Durham, L. E., Kirkham, B. W., & Taams, L. S. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0529-9 · Cited by 49
The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney
Ramani, K., Garg, A. V., Jawale, C. V., Conti, H. R., Whibley, N., Jackson, E. K., Shiva, S. S., Horne, W., Kolls, J. K., Gaffen, S. L., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005952 · Cited by 43
Carrascosa, J. M., & del Alcázar, E. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1454835 · Cited by 44
“3% ADA has been reported for secukinumab [41],”
BackgroundInfluentialNew insights into the function of Interleukin-25 in disease pathogenesis
Yuan, Q., Peng, N., Xiao, F., Shi, X., Zhu, B., Rui, K., Tian, J., & Lu, L. (2023) · Biomarker Research · doi:10.1186/s40364-023-00474-9 · Cited by 54
Morizane, S., Mukai, T., Sunagawa, K., Tachibana, K., Kawakami, Y., & Ouchida, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1239598 · Cited by 46
Cochez, P. M., Michiels, C., Hendrickx, E., Belle, A. B. V., Lemaire, M. M., Dauguet, N., Warnier, G., de Heusch, M., Togbe, D., Ryffel, B., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546070 · Cited by 49
Tłustochowicz, W., Rahman, P., SERIOLO, B., Krammer, G., Porter, B. O., Widmer, A., & Richards, H. B. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150117 · Cited by 46
“Immunogenicity assessments to detect anti-secukinumab antibodies were performed using the Meso Scale Discovery bridging assay 20 following a 3-tier approach (screening, confirmation, and titration) 21 .”
BackgroundMethodIL-23/IL-17 axis in spondyloarthritis-bench to bedside
Raychaudhuri, S. P., & Raychaudhuri, S. K. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3263-4 · Cited by 46
“IL-17A Secukinumab [42–44] Fully human, IgG1κ FDA approved for psoriasis and psoriatic arthritis”
BackgroundAbuHilal, M., Walsh, S. R., & Shear, N. H. (2016) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416651605 · Cited by 46
“Secukinumab-associated neutropenia cases were transient and reversible.(37) Neutralizing antibodies to secukinumab were reported in less than 1% in the ERASURE and FIXTURE but were not associated with reduced efficacy.”
BackgroundResultInfluentialConsiderations for Systemic Treatment of Psoriasis in Obese Patients
Gisondi, P., Giglio, M. D., & Girolomoni, G. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0211-7 · Cited by 46
Tahir, H., Deodhar, A. A., Genovese, M. C., Takeuchi, T., Aelion, J. A., den Bosch, F. E. V., Hämmerle, S. P., & Richards, H. B. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-017-0086-y · Cited by 47
“Safety data from this trial confirmed the safety profile of secukinumab as seen in the phase 3 trials in psoriasis [10], PsA [12] and AS [13].”
MethodChamps, B., Degboé, Y., Barnetche, T., Cantagrel, A. G., Ruyssen‐Witrand, A., & Constantin, A. (2019) · RMD Open · doi:10.1136/rmdopen-2018-000763 · Cited by 49
T cell epitope mapping of secukinumab and ixekizumab in healthy donors
Spindeldreher, S., Karle, A. C., Correia, E., Tenon, M., Gottlieb, S., Huber, T., Maillère, B., & Kolbinger, F. (2020) · mAbs · doi:10.1080/19420862.2019.1707418 · Cited by 48
Brownstone, N. D., Thibodeaux, Q. G., Reddy, V. D., Myers, B. A., Chan, S. Y., Bhutani, T., & Liao, W. J. (2020) · Dermatology and Therapy · doi:10.1007/s13555-020-00377-9 · Cited by 42
Galluzzo, M., Talamonti, M., Atzori, L., Bardazzi, F., Campanati, A., Cesare, A. D., Diotallevi, F., Flori, M. L., Mugheddu, C., Offidani, A., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2029841 · Cited by 43
Sun, X., Cui, Z., Wang, Q., Liu, L., Ding, X., Wang, J., Cai, X., Li, B., & Li, X. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103530 · Cited by 42
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris
Kolios, A. G. A., Yawalkar, N., Anliker, M. D., Boehncke, W., Borradori, L., Conrad, C., Gilliet, M. F., Häusermann, P., Itin, P. H., Laffitte, E., et al. (2016) · Dermatology · doi:10.1159/000445681 · Cited by 48
Nemoto, O., Hirose, K., Shibata, S., Li, K., & Kubo, H. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16236 · Cited by 45
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT 3
Tang, L., He, S., Wang, X., Liu, H., Zhu, Y., Feng, B., Su, Z., Zhu, W., Liu, B., Xu, F., et al. (2018) · Experimental Dermatology · doi:10.1111/exd.13511 · Cited by 47
Papp, K. A., Gooderham, M., Jenkins, R., Vender, R., Szepietowski, J. C., Wagner, T., Hunt, B., Souberbielle, B., & on behalf of the NEPTUNE investigators (2019) · British Journal of Dermatology · doi:10.1111/bjd.17195 · Cited by 42
Cameron, C. G., Hutton, B., Druchok, C., McElligott, S. C., Nair, S. C., Schubert, A., Situ, A., Varu, A., & Villacorta, R. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0065 · Cited by 46
Pavelká, K., Kivitz, A., Dokoupilová, E., Blanco, R., Maradiaga, M., Tahir, H., Wang, Y., Porter, B. O., Stefanska, A., Richards, H. B., et al. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11102 · Cited by 46
“Secukinumab, a fully human monoclonal antibody that directly inhibits IL-17A, has demonstrated significant improvement in the signs and symptoms of patients with AS (9,10), psoriasis (11), and psoriatic arthritis (12–14) and is approved for the treatment of these diseases, offering an alternate therapeutic option for…”
BackgroundKerkering, J., Muinjonov, B., Rosiewicz, K. S., Diecke, S., Biese, C., Schiweck, J., Chien, C., Zocholl, D., Conrad, T., Paul, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164637 · Cited by 41
“The matter is less clear for IL-17A, which is used as treatment target for psoriasis (43) and ankylosing spondylitis (44).”
IL-17 in osteoarthritis: A narrative review
Xiao, J., Zhang, P., Cai, F.-L., Luo, C., Pu, T., Pan, X.-L., & Tian, M. (2023) · Open Life Sciences · doi:10.1515/biol-2022-0747 · Cited by 61
The roles of T cells in psoriasis
Zhang, P., Su, Y., Li, S., Chen, H., Wu, R., & Wu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1081256 · Cited by 64
Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis
Alunno, A., Carubbi, F., Cafaro, G., Pucci, G., Battista, F., Bartoloni, E., Giacomelli, R., Schillaci, G., & Gerli, R. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084284 · Cited by 41
“As far as plaque psoriasis is concerned, the Phase III ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis) trials reported that secukinumab is…”
BackgroundZweegers, J., Otero, M., van den Reek, J. M. P. A., van Lümig, P. P. M., Driessen, R. S., Kievit, W., Seyger, M. M. B., van de Kerkhof, P. C. M., & de Jong, E. M. G. J. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2276 · Cited by 50
Schwensen, J. F. B., Clemmensen, A., Sand, C., Gniadecki, R., Skov, L., Zachariae, C. O. C., Iversen, L., Rasmussen, M. K., & Thomsen, S. F. (2017) · Dermatologic Therapy · doi:10.1111/dth.12550 · Cited by 41
“In addition, we found that the patients’ quality of life assessed by Dermatology Quality of Life Index (DLQI) improved during the treatment period, in accordance with observations from prior phase 3 trials (Langley et al., 2014).”
BackgroundResultInfluentialHuang, Y., & Tsai, T. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0310-5 · Cited by 41
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.